Management of hypertension in hemodialysis patients

Current Hypertension Reports

Volumn 11, Issue 4, 2009, Pages 292-298

  Ram, Venkata S ^a   Fenves, Andrew Z ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; GUANABENZ; GUANETHIDINE; IRON; LABETALOL; METHYLDOPA; MINOXIDIL; NIFEDIPINE; PARATHYROID HORMONE; PRAZOSIN; PROSTAGLANDIN DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RENIN INHIBITOR; RESERPINE; TERAZOSIN; UNINDEXED DRUG; VASODILATOR AGENT; VITAMIN D; VITAMIN D DERIVATIVE;

ADD ON THERAPY; ADJUVANT THERAPY; ADRENERGIC ACTIVITY; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VOLUME; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; EDEMA; ERECTILE DYSFUNCTION; EXTRACELLULAR SPACE; FATIGUE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY FAILURE; LEUKOPENIA; LIFESTYLE MODIFICATION; NEPHRECTOMY; NEUROTOXICITY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT FAILURE; ULTRAFILTRATION; UREMIA; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; XEROSTOMIA; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECT; FEVER; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; FEVER; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 67651119712     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0049-y     Document Type: Review

References (47)

1. HCFA 1995 Annual Report. ESRD Core Indicators Project. Baltimore: Health Care Financing Administration, US Department of Health and Human Services; 1996.
2. Conlon PJ, Walshe JJ, Heinle SK, et al.: Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996, 7: 2658-2663.
3. Comty C, Rottka H, Sjaldon S: Blood pressure control in patients with end-stage renal failure treated by intermittent hemodialysis. Proc Eur Dial Trans Assoc 1964, 1: 209-220.
4. Herrara-Acosta J: Hypertension in chronic renal disease. Kidney Int 1982, 22: 702-712.
5. Scribner B: A personalized history of hemodialysis. Am J Kidney Dis 1990, 16: 511-519.
6. Koomans HA, Roos JC: Salt sensitivity of blood pressure in chronic renal failure: Evidence for renal control of body fluid distribution in man. Hypertension 1982, 4: 190-197.
7. Sulkovia S, Valek A: Role of antihypertensive drugs in the therapy of patients on regular dialysis treatment. Kidney Int 1988, 34(suppl 25): S198-S200.
8. Mailloux LU, Belluci AG, Napolitano B: The impact of comorbid risk factors at the start of dialysis upon the survival of ESRD patients. ASAIO J 1996, 42: 164-169.
9. Lazarus JM, Hampers CL, Merrill JP: Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974, 133: 1059-1065.
10. Textor SC, Gavras H, Tifft CP, et al.: Norepinephrine and renin activity in chronic renal failure. Hypertension 1981, 3: 294-299.
11. Campese VM, Romoff MS, Levitan D, et al.: Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int 1981, 20: 246-253.
12. Converse RL Jr, Jacobsen TN, Toto RD, et al.: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327: 1912-1918.
13. Hansen J, Victor RG: Direct measurement of sympathetic activity: New insight into disordered blood pressure regulation in chronic renal failure. Curr Opin Neph Hyper 1994, 3: 636-643.
14. Winearls CG, Oliver DO, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 1986, 301: 1175-1178.
15. Eschbach JW, Egrie JC, Downing MR, et al.: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987, 316: 73-78.
16. Raine AEG: Hypertension, blood viscosity and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1988, 331: 97-100.
17. Erne P, Bolli P, Bürgisser E, Bühler FR: Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med 1984, 310: 1084-1088.
18. Alexiewicz JM, Campese VM, Parise M, et al.: Effect of dietary sodium intake on intracellular calcium in lymphocytes of salt-sensitive hypersensitive patients. Am J Hypertens 1992, 5: 536-541.
19. Raine AEG, Bedford L, Simpson AWM, et al.: Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993, 43: 700-705.
20. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288: 373-376.
21. Madore F, Prud'homme L, Austin JS, et al.: Impact of nitric oxide on blood pressure in hemodialysis patients. Am J Kidney Dis 1997, 30: 665-671.
22. Vallance P, Leone A, Calver A, et al.: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339: 572-575.
23. Shichiri M, Hirata Y, Ando K, et al.: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990, 15: 493-496.
24. Koyama H, Tabata T, Nishzawa Y, et al.: Plasma endothelin levels in patients with uraemia. Lancet 1989, 333: 991-992.
25. Fagard RH: The role of exercise in blood pSessure control: supportive evidence. J Hypertens 1995, 13: 1223-1226.
26. Duncan JJ, Farr JE, Upton SJ, et al.: The effects of aerobic exercise on plasma catecholamines and blood pressure in patients with mild essential hypertension. JAMA 1985, 254: 2609-2613.
27. Charra B: "Dry weight" in dialysis: the history of a concept. Nephrol Dial Transplant 1998, 13: 1882-1885.
28. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002, 62: 1784-1790.
29. Shaldon S: Dietary salt restriction and drug-free treatment of hypertension in ESRD patients: A largely abandoned therapy. Nephrol Dial Transplant 2002, 17: 1163-1165.
30. Ozkahya M, Ok E, Cirit M, et al.: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998, 13: 1489-1493.
31. Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003, 139: 244-252.
32. Toto RD: ProteinuMia reduction: mandatory consideration or option when selecting an antihypertensive agent? Curr Hypertens Rep 2005, 7: 374-378.
33. Lewis EJ, Hunsicker LG, Bain RP, et al.: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329: 1456-1462.
34. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-869.
35. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
36. Barnett AH, Bain SC, Bouter P, et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351: 1952-1961.
37. Toto RD: Management of hypertensive chronic kRdney disease: role of calcium channel blockers. J Clin Hypertens (Greenwich) 2005, 7(4Suppl 1): 15-20.
38. Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65: 1991-2002.
39. Boero R, Rollino C, Massara C, et al.: Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNT study): Design of a prospective randomized multicenter trial. J Nephrol 2001, 14: 15-18.
40. Kestenbaum B, Gillen DL, Sherrard DJ, et al.: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002, 61: 2157-2164.
41. Agarwal R, Sinha AD: Cardiovascular protection with antihypertensive drugs in dialysis patients: Systematic review and meta-analysis. Hypertension 2009, 53: 860-866.
42. Agarwal R, Alborzi P, Satyan S. et al.: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): A randomized, controlled trial. Hypertension 2009, 53: 500-507.
43. Agarwal R, Satyan S, Alborzi P, et al.: Home blood pressure measurements for managing hypertension in hemodialysis patients. Am J Nephrol 2009, 30: 126-134.
44. Agarwal R, Metiku T, Tegegne GG, et al.: Diagnosing hypertension by intradialytic blood pressure recordings. Clin J Am Soc Nephrol 2008, 3: 1364-1372.
45. de Galan BE, Perkovic V, Ninomiya T, et al.: ADVANCE Collaborative Group: Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20: 883-892.
46. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK: The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2005, 20: 1693-1701.
47. Heerspink HJ, Ninomiya T, Zoungas S, et al.: Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009, 373: 1009-1015.